Comparing metabolic and immune profiles in primary CNS diffuse large B‑cell lymphoma

Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma Based on Metabolomics and Immunomics

This study will test whether people with primary CNS diffuse large B‑cell lymphoma have different metabolic and immune patterns compared with lymphoma patients without CNS involvement and with healthy donors.

Quick facts

• Study type: Observational
• Enrollment: 20 (estimated)
• Ages: 18 Years to 75 Years
• Sex: All
• Sponsor: Fujian Medical University (other)
• Drugs / interventions: chemotherapy
• Locations: 1 site (Fuzhou, Fujian)
• Trial ID: NCT07188077 on ClinicalTrials.gov

What this trial studies

This is a prospective cohort study comparing metabolic and immunomic features between newly diagnosed primary CNS diffuse large B‑cell lymphoma patients, pathologically confirmed DLBCL patients without CNS involvement, and age- and sex-matched healthy donors. Baseline clinical information and biological samples will be collected, with PCNSL patients required to be treatment‑naïve at baseline. PCNSL participants will be followed every three months and asked to return sooner if symptoms develop. Laboratory analyses will profile metabolic signatures and immune characteristics to identify differences associated with CNS involvement.

Who should consider this trial

Good fit: Adults aged 18–75 with newly diagnosed, treatment‑naïve primary CNS diffuse large B‑cell lymphoma who can provide informed consent and have complete imaging and pathology data are the intended participants.

Not a fit: Patients with other active systemic malignancies, severe infections or organ failure, recent antimetabolite or chemotherapy use, pregnant or lactating women, or those with serious psychiatric or cognitive impairment are unlikely to benefit.

Why it matters

Potential benefit: If successful, the work could reveal metabolic or immune markers that improve diagnosis, prognosis, or guide more targeted therapies for patients with PCNSL.

How similar studies have performed: Molecular and immune profiling has produced useful biomarkers in systemic DLBCL, but applying metabolic and immunomic analyses specifically to PCNSL is relatively novel and not yet widely validated.

Eligibility criteria

Inclusion Criteria:

1. Aged between 18 and 75 years.
2. The case group must have a confirmed diagnosis of primary central nervous system lymphoma (PCNSL) and must not have received any antitumor therapy prior to baseline sample collection.
3. Must sign an informed consent form, agree to participate in this study, and provide samples and clinical information as required.
4. Case group patients must have complete supporting imaging and pathology data.

Exclusion Criteria:

1. Presence of other systemic malignancies.
2. Presence of severe infections or metabolic disorders.
3. Use of antimetabolites or chemotherapy drugs within one week prior to sample collection.
4. Pregnant or lactating women.
5. Concurrent severe internal medical conditions (e.g., end-stage renal disease, heart failure, liver failure).
6. Patients unable to complete study requirements due to psychiatric disorders or cognitive impairment.

Where this trial is running

Fuzhou, Fujian

• The First Affiliated Hospital of Fujian Medical University — Fuzhou, Fujian, China (RECRUITING)

Study contacts

• Study coordinator: 晓权 纪

Conditions: Primary Central Nervous System Lymphoma, Diffuse Large B-Cell Lymphoma